Drugs / AZD1043
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07511205 | Mar 2026 → Apr 2027 expected | obesity disorder | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD1043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07511205 ↗ |
| Route | Intravenous | “Via Subcutaneous and/or Intravenous Administration” NCT07511205 ↗ |
| Route | Subcutaneous | “Via Subcutaneous and/or Intravenous Administration” NCT07511205 ↗ |